admin – Page 554 – Get News Story

Creamy Flavors Named #1 Ice Cream Shop in Boca Raton by CX Research Institute

Independent research report ranks West Boca dessert hub highest for locally made ice cream, menu diversity, and family‑friendly experience.

Boca Raton, FL – CX Research Institute announced the publication of its comprehensive research report evaluating the best ice cream and frozen dessert shops serving Boca Raton, Florida. Creamy Flavors earned the top ranking with a score of 92 out of 100 points, leading nine other concepts in a structured comparative analysis of product quality, menu diversity and innovation, customer experience, brand positioning, pricing transparency, and operational accessibility.

The research report, titled “Best Ice Cream Shops in Boca Raton, FL (Top‑Rated & Must‑Try Ice Cream Shops): A Research‑Based Comparative Analysis,” assesses a mix of independent shops and franchise locations specializing in ice cream, frozen custard, frozen yogurt, Italian ice, and related frozen desserts.

Creamy Flavors: Locally Made Ice Cream and Multi‑Category Dessert Destination

Creamy Flavors, a locally owned shop in West Boca Raton, is positioned as a comprehensive dessert hub offering locally manufactured premium ice cream alongside frozen yogurt, fruit‑forward or Italian‑ice style options, sundaes, milkshakes, smoothies, and bubble tea. Operating from a busy neighborhood plaza, it has become a go‑to destination for families, students, and local residents seeking a broad, customizable dessert experience.

The report notes that Creamy Flavors’ primary strength lies in its product philosophy and breadth. The shop manufactures its ice cream locally rather than acting purely as a reseller and clearly structures its menu into distinct categories, signaling deliberate product design rather than ad‑hoc expansion. Sugar‑free and non‑dairy options are explicitly highlighted and framed as suitable for diabetic and lactose‑sensitive customers, making the shop notably inclusive compared to many competitors.

Customer experience indicators point to a clean, brightly lit, family‑friendly environment, with staff characterized as attentive and welcoming. Toppings, including options like popping boba, support extensive customization, allowing guests to tailor desserts to their preferences. The shop’s digital infrastructure, including an online menu, delivery or online ordering channels, and clear location and hours information, further enhances accessibility and convenience for both in‑shop visits and take‑home pints and quarts.

Top Score of 92/100 Reflects Transparency, Inclusivity, and Experience

Under the CX Research Institute’s 100‑point framework, Creamy Flavors received:

23 out of 25 points for Product Quality & Ingredient Transparency, reflecting locally manufactured ice cream, clear category definitions, and a premium positioning.
19 out of 20 points for Menu Diversity & Innovation, based on its combination of ice cream, frozen yogurt, sundaes, shakes, smoothies, fruit‑forward options, and bubble tea, plus sugar‑free and non‑dairy choices.
19 out of 20 points for Customer Experience & Store Environment, recognizing a family‑oriented, comfortable in‑store setting with strong appeal to mixed‑preference groups.
14 out of 15 points for Brand Positioning & Market Presence, acknowledging its identity as a neighborhood dessert hub and locally focused independent business.
8 out of 10 points for Pricing Transparency & Value Communication, supported by visible menus and accessible pricing through online channels.
9 out of 10 points for Operational Transparency & Accessibility, reflecting clear digital communication of hours, location, and ordering options.

The report concludes that Creamy Flavors is best suited for families and mixed‑preference groups wanting multiple dessert formats in one visit, consumers who require sugar‑free or non‑dairy options, and households that want the flexibility of both in‑store treats and take‑home containers. The main trade‑off noted is that its broad menu and multi‑format concept may be less appealing to guests who prefer tightly focused single‑style concepts, such as pure frozen custard or Italian ice specialists.

Rankings Showcase Distinct Dessert Formats Across Boca Raton

Using the same 100‑point scoring framework, CX Research Institute evaluated ten ice cream and frozen dessert shops that operate in or clearly serve Boca Raton and maintain sufficient digital transparency for structured assessment. The ranked results are:

Rank	Shop	Total Score (100)
1	Creamy Flavors	92
2	Whit’s Frozen Custard	85
3	Jeremiah’s Italian Ice	84
4	Larry’s Ice Cream & Cafe	82
5	Menchie’s Frozen Yogurt	81
6	Scoops Ice Cream & Milkshake Bar	78
7	Brendy’s Yogurt & Ice Cream	73
8	Brendy’s at 18th Street	69
9	Brendy’s at the Reserve	68
10	Brendy’s of Delray	69

Whit’s Frozen Custard ranks second as a dense, egg‑based frozen custard specialist with daily in‑store production, rotating flavors, and a neighborhood custard‑shop feel. Jeremiah’s Italian Ice takes third place with its extensive Italian ice flavor library and Gelati format layering Italian ice with soft‑serve, appealing to guests who prioritize flavor variety and lighter, water‑based desserts. Larry’s Ice Cream & Cafe is recognized for combining a full ice cream parlor with a comfort‑food cafe in a nostalgic, boardwalk‑inspired environment, while Menchie’s Frozen Yogurt performs strongly as a self‑serve, family‑friendly yogurt concept with documented kosher status at the Garden Shops at Boca location and broad dietary options.

Scoops Ice Cream & Milkshake Bar is highlighted for its premium, visually striking milkshake creations, whereas Brendy’s Yogurt & Ice Cream and its neighborhood locations are noted as familiar, straightforward dessert options that emphasize convenience and local recognition over extensive menu innovation or ingredient storytelling.

Research Methodology and Consumer Guidance

The Boca Raton ice cream and frozen dessert report was developed through desk‑based research using only publicly available sources such as official business websites, store‑level and brand‑level location pages, online menus and ordering platforms, local news and chamber of commerce releases, and public business directories. No taste tests, mystery shopping, private operational data, or regulatory records were used.

Each shop was evaluated against six categories: Product Quality & Ingredient Transparency, Menu Diversity & Innovation, Customer Experience & Store Environment, Brand Positioning & Market Presence, Pricing Transparency & Value Communication, and Operational Transparency & Accessibility. Where documentation for a criterion was absent or ambiguous, the Institute assigned conservative scores, rewarding transparency and penalizing incomplete public information without speculating about unreported strengths.

The report also provides cross‑shop observations, including the contrast between format specialists and broad menu operators, variability in dietary accommodation clarity, and differences in digital ordering maturity. A consumer decision checklist helps guests align their preferences around product type, dietary needs, budget, and experience with the shop profiles in the study.

About CX Research Institute

CX Research Institute is an independent research organization dedicated to providing objective, data‑driven analysis of consumer‑facing businesses across food, hospitality, home services, healthcare, financial services, and other sectors. Its mission is to help individuals and organizations make informed decisions through comprehensive research reports, comparative analyses, and transparent scoring methodologies.

All CX Research Institute evaluations follow explicit criteria and repeatable rubrics, and the organization does not accept compensation from evaluated businesses. This commitment to methodological rigor and editorial independence is intended to preserve research integrity and consumer trust.

The complete research report, “Best Ice Cream Shops in Boca Raton, FL (Top-Rated & Must-Try Ice Cream Shops): A Research-Based Comparative Analysis,” including detailed shop profiles, scoring methodology, cross-shop observations, consumer checklists, and a frequently asked questions section, is available at:

https://cxresearchinstitute.org/research-paper/best-ice-cream-shops-in-boca-raton-fl/

Media Contact
Company Name: Creamy Flavors
Email: Send Email
Phone: +1 561-672-7703
Address:23001b FL-7
City: Boca Raton
State: Florida 33428
Country: United States
Website: https://www.creamyflavors.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Creamy Flavors Named #1 Ice Cream Shop in Boca Raton by CX Research Institute

Drain Great Plumbing Services Named #1 Plumber in Monrovia by CX Research Institute

Independent research report ranks Monrovia contractor highest for service transparency, licensing communication, and residential and emergency plumbing capabilities

Monrovia, CA – CX Research Institute announced the publication of its comprehensive research report evaluating the best plumbers serving Monrovia, California, and the surrounding San Gabriel Valley. Drain Great Plumbing Services earned the top ranking with a score of 91 out of 100 points, leading nine other plumbing companies in a structured comparative analysis of service range, licensing and compliance transparency, customer experience architecture, pricing communication, local reputation, and operational infrastructure.

The research report, titled “Best Plumbers in Monrovia, CA (Top-Rated & Licensed Plumbing Services): A Research-Based Comparative Analysis,” was developed to give homeowners, property managers, and facilities professionals a clear, data-driven framework for selecting qualified, licensed plumbing contractors in a market where online documentation quality varies widely between providers.

Drain Great Plumbing Services, Monrovia-Focused and Operationally Transparent

Drain Great Plumbing Services is the top-ranked plumbing service provider in the Monrovia analysis, earning a composite score of 91 out of 100 points. The company serves Monrovia and the broader San Gabriel Valley with documented residential and commercial plumbing services, positioning itself as a local, accessibility-focused contractor rather than a generic regional listing.

The report notes that Drain Great Plumbing Services’s public-facing presence demonstrates a level of service documentation and operational clarity that distinguishes it from the broader field. Its website presents a structured overview of service categories, including drain cleaning, sewer services, water heater work, leak detection, and general plumbing repair, and communicates availability for both scheduled and emergency work through a clear and accessible interface.

CX Research Institute highlights that Drain Great Plumbing Services’ licensing and regulatory communications align with California’s contractor transparency norms, reflecting awareness of C‑36 Plumbing Contractor requirements and providing Monrovia consumers with a higher degree of assurance than competitors whose sites say little about compliance. The company’s service area documentation clearly encompasses Monrovia, supporting its inclusion and primary ranking in the study.

Top Score of 91/100 Driven by Service Clarity and Customer Experience

Under the Institute’s 100-point framework, Drain Great Plumbing Services Services scored 23 out of 25 in Service Range and Technical Transparency, 18 out of 20 in Licensing, Bonding and Compliance Transparency, 19 out of 20 in Customer Experience and Service Model, 13 out of 15 in Pricing Transparency and Value Positioning, 9 out of 10 in Reputation and Local Market Presence, and 9 out of 10 in Operational Infrastructure and Accessibility, for a total of 91 out of 100.

The report identifies several key differentiators behind this performance:

Service transparency: Drain Great Plumbing Services publicly documents a comprehensive range of plumbing services, including drains, sewers, water heaters, leak detection, and broader residential needs, enabling prospective clients to assess fit before calling.
Emergency positioning: Its communications reflect awareness of emergency demand and position the company as available for urgent residential issues, which is a meaningful differentiator in a market where not all providers clearly explain their emergency model.
Digital accessibility: The website supports multiple contact pathways and a user-friendly structure that reduces friction in the inquiry process, signaling investment in client-facing infrastructure.
Operational clarity: Service area boundaries, available services, and basic operational parameters are communicated with a degree of clarity that outperforms most evaluated competitors.
Regulatory communication: Licensing and compliance-related statements reflect alignment with California standards, giving consumers a more reliable basis for initial screening.

According to the Institute, Drain Great Plumbing Services is best suited for residential homeowners seeking a transparent, accessible, and well-documented plumbing contractor for routine service, maintenance, and emergency response in Monrovia and the San Gabriel Valley, and is also a credible option for small commercial operators who require clear scope documentation.

Ranked Results Show Wide Transparency Gap in Monrovia Market

The CX Research Institute evaluation applied the same 100-point scoring framework to ten plumbing companies with documented service in Monrovia or immediately adjacent western San Gabriel Valley communities. The ranked results are:

Rank	Company	Total Score (100)
1	Drain Great Plumbing Services	91
2	Western Rooter	85
3	Advantage Plumbing & Rooter	80
4	1 Day Rooter & Plumbing	76
5	Hassle-Free Plumbing	73
6	Ace Pelizon Plumbing	70
7	Power Pro Plumbing	68
8	DP Plumbing & Sewer Inc.	65
9	Drainflow Solutions & Plumbing LLC	62
10	PRO PLUMBERS	56

The report emphasizes that the 35-point spread between Drain Great Plumbing Services and the lowest-ranked provider primarily reflects differences in documentation quality and transparency, not direct field-audit judgments about service workmanship. It notes that drain and sewer services are the most consistently documented categories across the market, while gas line work, trenchless sewer, and other specializations are addressed in detail by fewer providers, requiring consumers with specific needs to scrutinize service descriptions closely.

Research Methodology and Homeowner Guidance

The Monrovia plumbing study was conducted as a desk-based research project using only publicly available information from official company websites and service area pages, the California Contractors State License Board public license search, City of Monrovia Building and Safety Division resources, Los Angeles County Department of Public Works standards, and applicable sections of the California Business and Professions Code and California Plumbing Code.

CX Research Institute’s six-category, 100-point framework assessed Service Range and Technical Transparency, Licensing, Bonding and Compliance Transparency, Customer Experience and Service Model, Pricing Transparency and Value Positioning, Reputation and Local Market Presence, and Operational Infrastructure and Accessibility, applying conservative scores where documentation was limited. The Institute recommends that Monrovia homeowners independently verify any plumber’s CSLB license status, confirm general liability and workers’ compensation coverage, request written estimates before authorizing work, clarify permit responsibilities for water heater replacements, repiping, sewer work, and gas line projects, and retain permit and inspection records for future transactions.

About CX Research Institute

CX Research Institute is an independent research organization dedicated to providing objective, data-driven analysis of professional service providers across home services, healthcare, financial services, and other consumer-facing sectors. Its mission is to help individuals and organizations make informed decisions through comprehensive research reports, comparative evaluations, and transparent, criteria-based methodologies that rely only on verifiable public information.

All research follows explicit scoring frameworks with repeatable rubrics and conservative interpretation of available evidence, and the Institute does not accept compensation from evaluated companies, maintaining strict editorial independence to protect research integrity.

The complete research report, “Best Plumbers in Monrovia, CA (Top-Rated & Licensed Plumbing Services): A Research-Based Comparative Analysis,” including detailed company profiles, scoring methodology, cross-company observations, homeowner checklists, and a frequently asked questions section, is available at:

https://cxresearchinstitute.org/research-paper/best-plumbers-in-monrovia-ca/

Media Contact
Company Name: Drain Great Plumbing Services
Email: Send Email
Phone: +1 888-778-4862
Address:219 Los Angeles Ave
City: Monrovia
State: California 91016
Country: United States
Website: https://draingreatplumbing.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Drain Great Plumbing Services Named #1 Plumber in Monrovia by CX Research Institute

Empathy in Medicine Initiative Launches Student Chapter Program to Expand Empathy-Focused Healthcare Leadership Opportunities

Empathy in Medicine Initiative (EMI), a student-led nonprofit founded in Great Neck, New York, announces a new Student Chapter Program enabling high school and college students to launch empathy-focused healthcare communication initiatives in their communities.

Great Neck, New York, USA – February 24, 2026 – The Empathy in Medicine Initiative (EMI), a student-led nonprofit organization dedicated to strengthening empathy and communication in healthcare, has announced the launch of its new Student Chapter Program. The initiative is designed to empower high school and college students to establish local EMI chapters that promote patient-centered communication through structured educational and community-based activities.

Founded by Kevin Lin, a student at Great Neck South High School in Great Neck, New York, EMI focuses on addressing a growing need within healthcare education: developing interpersonal and communication skills alongside academic and technical training. The newly introduced chapter program provides a formal framework that allows students to organize empathy-centered initiatives while gaining leadership and service experience connected to healthcare environments.

Expanding student leadership through structured empathy initiatives

The Student Chapter Program enables participating students to create school-based or community-based clubs aligned with EMI’s mission. Chapters will host communication skills workshops, empathy-focused events, and community education projects that emphasize respectful patient interaction and effective communication practices. These activities are intended to help participants better understand the human aspects of healthcare while encouraging collaboration and service engagement within their local communities.

To support implementation, EMI provides participating chapters with practical resources designed to simplify the process of launching and maintaining student organizations. These resources include structured toolkits, meeting and event planning guides, communication scripts, and training materials. The standardized materials aim to ensure consistency across chapters while allowing students flexibility to adapt initiatives to their specific school or regional needs.

Early traction highlights growing demand among students

The organization reports early interest and measurable engagement through its online platform, which currently shows 233 registered users and 73 submitted applications, with 69 applications pending or under review. This early traction demonstrates increasing student demand for organized programs that combine healthcare exploration with leadership development and measurable community impact.

As healthcare systems continue to emphasize patient-centered care, communication skills are increasingly recognized as essential competencies for future healthcare professionals. EMI’s chapter model provides students with a structured pathway to explore these skills before entering professional training environments, helping bridge the gap between academic preparation and real-world interpersonal experience.

“Too many students want to do meaningful healthcare-related service and leadership, but they do not have a clear structure to start,” said Kevin Lin, founder of the Empathy in Medicine Initiative and a student at Great Neck South High School in Great Neck, New York. “Our chapter program gives high school and college students a practical toolkit to launch empathy-focused clubs and projects that create measurable impact in their schools and communities.”

Providing accessible tools for sustainable impact

A key component of the Student Chapter Program is accessibility. EMI designed its resources to reduce administrative barriers that often prevent students from launching new organizations. By offering ready-to-use templates, training frameworks, and operational guidance, the program allows students to focus on meaningful engagement rather than organizational logistics.

The initiative also encourages collaboration between students, educators, and local communities. Chapters may organize awareness events, peer-learning sessions, and service projects that highlight the importance of empathy in healthcare communication. Through these activities, students can develop leadership experience while contributing to broader conversations around compassionate care and effective patient interaction.

Students interested in participating can learn more about the program, access available resources, and apply to start a chapter by visiting https://empathyinmedicine.org/.

About Empathy in Medicine Initiative

Empathy in Medicine Initiative (EMI) is a student-led nonprofit organization focused on advancing empathy and communication in healthcare. The organization provides educational resources, structured programs, and leadership opportunities that enable students to explore patient-centered communication while creating measurable community impact.

Media Contact
Company Name: Empathy in Medicine Initiative
Contact Person: Kevin Lin
Email: Send Email
Country: United States
Website: https://empathyinmedicine.org/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Empathy in Medicine Initiative Launches Student Chapter Program to Expand Empathy-Focused Healthcare Leadership Opportunities

Teatime with Miss Liz Season 7 Announces Powerful March 2026 Lineup & Joins Global Podcasthon Movement

Global Voices. Courageous Conversations. Awakening Humanity Through Truth, Experiences, Awareness.

Cornwall, Ontario, Canada – Feb 24, 2026 – Season 7 of Teatime with Miss Liz launches this March with one of its most expansive and impactful lineups to date, uniting 17 voices across North America and Europe in conversations that confront trauma, identity, leadership, justice, healing, and human resilience. Hosted by Elizabeth Jean Olivia Gagnon, known globally as Miss Liz, the series continues its evolution from podcast to international storytelling platform dedicated to transformation through lived experience.

Rooted in Miss Liz’s signature framework, “Your T-E-A – Truth, Experiences, Awareness,” Teatime with Miss Liz creates space for guests to share journeys often left untold: recovery after adversity, reform after injustice, purpose after loss, and leadership born from hardship. Season 7’s March programming reflects the show’s guiding theme, Global Voices. Courageous Conversations., amplifying stories that bridge cultures while centering emotional honesty and personal accountability.

“Teatime is where humanity meets,” said Miss Liz. “When we share truth without masks, we awaken awareness, not only in ourselves but in everyone listening.”

Podcasthon 2026 Participation

In a major global collaboration, Miss Liz will also join Podcasthon 2026, taking place March 14–20, alongside more than 2,500 podcasts worldwide in a coordinated effort to amplify charitable organizations and social causes through audio storytelling. Backed by major industry leaders and platforms, Podcasthon represents a growing movement toward purpose-driven media and collective impact.

Aligned with her Season 7 mission, Miss Liz will dedicate a special Teatime episode to spotlight a selected cause, reinforcing her long-held belief that storytelling builds unity, compassion, and global awareness.

March 2026 Guest Highlights

Season 7’s March calendar brings together advocates, authors, leaders, survivors, and visionaries whose work spans healing, prison reform, entrepreneurship, emotional regulation, identity exploration, humanitarian action, and love-centered leadership.

l March 3: Adriene Caldwell; John David Graham

l March 5: Kelly Earle; Matt Melvin

l March 10: Shamayne Olivia Kottas

l March 12: Nichole Lee; Laura Price

l March 17: Kim Weiler Matuko & John Henry; Michael Walton

l March 19: D.A. Murray; Dwayne Brenna

l March 24: Dr. Ron Stotts; Dr. Laila Nayab-Murshidi

l March 26: Anne Alexander Sieder; Laura Yates

l March 31: Scarlett Lewis; Rob Thomas

Each episode continues Teatime’s hallmark format: intimate, unscripted dialogue that centers lived experience as a catalyst for growth and social awareness.

A Platform for Transformation

Now in its seventh season, Teatime with Miss Liz has grown into a global platform recognized for elevating authentic storytelling across borders and backgrounds. Miss Liz’s message remains a defining force behind the show’s impact:

“They say I can’t. I say watch me.”

“Adversity is as valuable as success, the cracks we hide are the doorways to transformation.”

By amplifying voices speaking to healing, justice awareness, conscious leadership, entrepreneurship, and identity, Season 7 positions Teatime not only as a podcast but as a movement grounded in compassion and accountability.

Episodes stream live and remain available for replay on YouTube, Spotify, and major podcast platforms worldwide.

About Teatime with Miss Liz

Teatime with Miss Liz is an international interview podcast and storytelling platform dedicated to transformation through Truth, Experiences, and Awareness (T-E-A). Hosted by Elizabeth Jean Olivia Gagnon, the series features global voices sharing journeys of resilience, healing, leadership, and social impact to foster understanding and human connection.

Media Contact
Company Name: Miss Liz’s Teatime
Contact Person: Elizabeth Jean Olivia Gagnon
Email: Send Email
City: Cornwall
State: Ontario
Country: Canada
Website: www.misslizsteatime.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Teatime with Miss Liz Season 7 Announces Powerful March 2026 Lineup & Joins Global Podcasthon Movement

Inspo Dental Announces Expansion and Welcomes Two Associate Dentists to Support Growing Patient Demand in Red Bank, NJ

Inspo Dental, a Red Bank, NJ dental practice, announces continued growth and the addition of two associate dentists joining in 2026 to expand patient access while maintaining personalized community-focused care.

Inspo Dental, a community-focused dental practice serving Red Bank and surrounding areas, has announced continued growth alongside the addition of two associate dentists, Dr. Virk and Dr. Junaely, who will officially join the practice in 2026. The expansion reflects increasing patient demand and the practice’s ongoing commitment to accessible, patient-centered dental care.

Since opening its doors, Inspo Dental has focused on combining advanced clinical dentistry with a supportive and transparent patient experience. The practice has steadily built strong relationships with individuals, families, and multi-generational households across the Red Bank community, earning recognition for its emphasis on comfort, education, and clear communication.

“We are incredibly grateful for the trust and support we’ve received since opening,” said Dr. Dorothy Lee of Inspo Dental. “Red Bank welcomed us from the very beginning, and it is because of our patients that we’ve been able to grow into the practice we are today.”

Meeting Community Needs Through Thoughtful Growth

As patient demand continues to increase, Inspo Dental’s decision to expand its clinical team marks a significant milestone in the practice’s development. The addition of Dr. Virk and Dr. Junaely is intended to improve appointment availability while preserving the personalized care experience that patients have come to expect.

According to the practice, both associate dentists were selected for their clinical expertise and shared commitment to compassionate, patient-first dentistry.

“Bringing new associate dentists onto our team allows us to better support our patients while maintaining the level of care and attention they value,” Dr. Lee said. “This growth is about strengthening our ability to serve the community responsibly.”

Focus on Comfort, Education, and Patient Confidence

Inspo Dental has distinguished itself locally through an approach centered on patient understanding and comfort. The practice prioritizes helping patients fully understand their oral health conditions, treatment options, and preventive care strategies.

Services range from routine dental checkups and restorative procedures to care tailored for individuals experiencing dental anxiety. By combining a calm clinical environment with a compassionate care philosophy, Inspo Dental aims to make dental visits more approachable for patients of all ages and backgrounds.

The practice emphasizes that expansion will not change its personalized approach; instead, it will allow the team to continue delivering attentive care while accommodating a growing patient base.

Strengthening Community Connections

Beyond clinical services, Inspo Dental views its growth as closely tied to its role within the Red Bank community. The practice remains actively engaged with local residents and businesses and credits community support as a key factor in its continued success.

Leadership describes the upcoming expansion as both a milestone and a responsibility — reflecting the trust patients have placed in the practice through referrals and long-term relationships.

The arrival of Dr. Virk and Dr. Junaely in 2026 aligns with Inspo Dental’s broader goal of providing accessible, relationship-driven dental care while adapting to the evolving needs of local residents.

Looking ahead, the practice plans to continue strengthening its position as a trusted neighborhood dental provider focused on long-term oral health, education, and patient comfort.

About Inspo Dental

Inspo Dental is a modern dental practice located in Red Bank, New Jersey, providing comprehensive, patient-centered dental care in a welcoming environment. The practice is dedicated to comfort, transparency, long-term oral health, and strong community connection.

Media Contact
Company Name: Inspo Dental
Contact Person: Brooke
Email: Send Email
Phone: 732-530-5111
Address:146 Maple Ave
City: Red Bank
State: New Jersey 07701
Country: United States
Website: https://www.inspodental.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inspo Dental Announces Expansion and Welcomes Two Associate Dentists to Support Growing Patient Demand in Red Bank, NJ

Fenix360, The Future Of Social Media, Scores Major Wins

FENIX360 Pte Ltd (“FENIX360”), a global artist & creator-centric social-media platform, today announced that it has entered into a definitive Share Subscription Facility agreement for up to USD 90 million with GEM Global Yield LLC SCS (“GEM”), a Luxembourg-based private alternative investment group.

The facility provides FENIX360 with a flexible equity financing structure to support the company’s continued global expansion, platform development and strategic alliances with leading regional players. FENIX360 has already onboarded more than 7,000 artist ambassadors for promotion in 2026 in their respective markets.

Under the terms of the agreement, upon Listing, FENIX360 may, at its sole discretion, issue registered and freely tradable common shares to GEM over the investment period, subject to customary conditions. The structure enables FENIX360 to control the timing and amount of capital drawn, aligning funding with corporate milestones and market conditions. As part of the transaction, FENIX360 has also issued warrants to GEM.

The transaction represents the largest creator-economy equity facility publicly announced in 2025, reflecting institutional confidence in FENIX360’s “Future of Social media” business model and international growth strategy, as the Company prepares for public listing.

Allan Mark Klepfisz, Chairman & Chief Executive Officer of FENIX360, commented:

“This agreement provides FENIX360 with substantial flexibility and long-term capital to execute our growth strategy. We view GEM as the ideal financial partner and are very pleased to partner with them as we continue to scale our platform globally.”

About FENIX360

FENIX360 is a global creator-focused social-media and entertainment platform designed to provide artists with greater control over content, dramatically higher percentages of revenue, a wide spectrum of monetization opportunities, and greatly enhanced engagement with fans. The platform integrates social networking, music and video distribution, merchandising, NFTs, financial & marketing tools, and gamified participation into a single powerful ecosystem.

Investment Contact: IR@fenix360.com

FENIX360 was represented in the transaction by Willkie Farr & Gallagher LLP.

About GEM Global Yield

GEM Global Yield LLC SCS (“GEM”) is a USD 3.4 billion alternative investment group that manages a diverse set of investment vehicles focused on emerging markets across the world, having completed over 570 transactions in 70 countries. GEM’s investment vehicles provide the group and its investors with a diversified portfolio of asset classes spanning the global private investing spectrum. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile, providing GEM and its partners with exposure to small-and mid-cap management buyouts, private investments in public equities (PIPEs), and select venture investments.

Media Contact
Company Name: fenix360
Contact Person: Media Relations
Email: Send Email
Country: Singapore
Website: https://www.fenix360.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fenix360, The Future Of Social Media, Scores Major Wins

The Future of AI-driven Revenue Cycle Management Inpatient

With the current pressured healthcare system, inpatient providers are constantly pressured to provide quality care to their patients and exert complicated administrative duties. The documentation process, the accuracy of coding, the regulations, and the billing laws are becoming increasingly complicated year after year. Due to this, a lot of valuable clinical time is usually wasted in paperwork and not in dealing with patients.

This is where the AI-Powered Charge Capture of Claimocity comes in – introducing a new dawn of efficiency, precision, and automation to the work of managing an inpatient revenue cycle.

The Increasing Burden of Inpatient Documentation

Patient care takes years to learn, not billing systems. However, the conventional process of billing requires physicians to handwrite charges, find diagnosis codes, test compliance conditions, and decode the continuously changing billing laws.

Such time-consuming activities may result in:

Lost billable opportunities.

Coding inaccuracies

Delayed reimbursements

Greater administrative stress.

Increased chances of misjudgment.

Even the most seasoned clinicians may easily fail to notice billable services when attending to a high number of patients. The documentation requirements are so complicated that entering the charges manually is ineffective and subject to making mistakes.

AI-based Intelligence that Operates Under the Hood

The solution offered by Claimacity brings a revolution to the workflow as it incorporates the use of advanced artificial intelligence directly into the documentation process. The system reads all clinical notes with meticulous detail, in real-time, and it automatically pulls out all billable charges in an extraordinarily accurate way.

The AI engine does the heavy lifting instead of the providers having to search for codes or comprehend billing regulations. It determines services provided and compares them against the regulatory standards, and makes sure that the billing is properly aligned.

This charge capture software gets rid of the guesswork that has been traditional with inpatient billing with the use of intelligent automation.

Streamlining the Provider Experience

The simplicity of AI-Powered Charge Capture can be considered one of the most potent features of Claimocity. The providers will not be required to divide their attention between clinical care and administrative documentation.

The process of work becomes immensely simple:

See the patient.
Sign and fill out the clinical note.
Automate the system to extract the billing.

No other steps, no manual charge entry, and no scanning through code libraries. The technology is also smooth in the background, and therefore, nothing is lost.

Such an efficient procedure will enable doctors to recover precious time, a time that can be diverted to treating patients, cooperatin,g and developing.

Increasing Accuracy and Limiting Revenue Leakage

In the inpatient setting, the leakage of revenue is a silent but important problem. Under-coding or mis-documentation of billable services causes healthcare organizations to lose revenue, which is a good representation ofthe care provided.

The AI-based charge capture software by Claimacity is an addition to financial performance because it:

Coding all billable services that are eligible.

Minimizing the risk of undercoding and overcoding.

Enhancing the accuracy of documentation.

Sensitizing adherence to existing billing principles.

The system is capable of continually analyzing clinical notes, and this makes sure that no detail is missed out. It enhances service-to-service correspondence by removing billing through recorded care.

The Compliance in the Complex Regulatory Environment

The laws of healthcare billing are in a constant flux. To remain in compliance, it is necessary to continue to educate, prepare new knowledge about the payer requirements, and care about documentation standards.

Systems with manual systems allow slip-ups to occur easily. But automation driven by AI comes with an element of built-in compliance intelligence. Documentation of the system is checked against existing billing requirements and indicates possible deviations before submission.

This initiative minimizes audit risk, promotes regulatory convergence, and generates more trust in the accuracy of the billing.

Improving Revenue Cycle Effectiveness

Efficiency in revenue cycle management has a direct influence on the finances of healthcare organizations. Failure to enter charges or correct codes on time may lengthen reimbursement periods and may put financial pressure on cash flows.

This charge capture software can streamline the billing cycle by extracting charges at the time of documentation, which are then automatically extracted and captured. However, the identification of charges occurs upon note completion, and this minimizes lag time between care provision and claim.

The result is:

Reduced turnaround times.

Fewer billing corrections

Increased efficiency in operations.

Less reliance on manual administrative procedures.

With the removal of administrative bottlenecks, healthcare teams would be able to work more strategically.

The Healthcare Organization Scale Empowerment

The complexity of the administrative aspect increases with the growth of the healthcare systems and the number of patients. Manual billing processes can also involve the need to increase the level of staff and other resources, which may considerably increase the cost of operations.

The scalability equation is altered with AI-driven automation. The solution offered by Claimacity can accommodate higher workloads in documentation without necessarily having to augment the administrative staff accordingly.

This will enable organizations to expand without much fear of their billing infrastructure being inaccurate, inefficient, and non-sustainable.

A High-End Product for Contemporary Healthcare Providers

The premium AI-Powered Charge Capture product provided by Claimocity is not an ordinary billing apparatus: it is a competitive edge. It will close the divide between care delivery and revenue optimization by offering automated extraction abilities and clinical intelligence.

Providers benefit from:

Less administrative anxiety.
More time for patient care
Simplified workflows
Greater billing confidence
Administrators enjoy:
Better financial performance.
Greater compliance monitoring.
Stronger revenue integrity
Expandable operational performance.

This highly sophisticated charge capture software is a glimpse into the future of inpatient billing, where improvement of technology augments human experience as opposed to making it difficult.

The Future of Charge Capture Is Here

The medical field is changing at a fast rate,e and technology should keep pace. The automation through AI is no longer a luxury; it is a mandatory tool for the organization that wants to stay afloat and competitive.

The AI-Powered Charge Capture is a tool that transforms the conventional documentation-to-billing procedure into a smart, efficient process by Claimacity. Through its accuracy in reading clinical notes and its ability to extract all the relevant charges, it helps to eliminate administrative burdens for providers and enhance revenue performance.

A company that values time and cannot afford to be wrong is in an industry where a strong charge capture software solution is a decisive move to operational excellence.

The future of inpatient billing is not manual; it is smart, automated, and will be created to allow providers to concentrate on the most important aspect: providing patients with high-quality care.

Media Contact
Company Name: Claimocity Inc.
Email: Send Email
Country: United States
Website: https://claimocity.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Future of AI-driven Revenue Cycle Management Inpatient

Hemophilia Clinical Trial Pipeline Shows Potential with Active Contributions from 80+ Key Companies | DelveInsight

DelveInsight’s, “Hemophilia Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Hemophilia Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight

Key Takeaways from the Hemophilia Pipeline Report

On February 11, 2026- Novo Nordisk A/S announced a study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study.
On February 05, 2026- Pfizer initiated a study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require “Early Termination” from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008.
On February 05, 2026- CSL Behring conducted a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
On February 05, 2026- Hoffmann-La Roche announced a phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
DelveInsight’s Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment.
The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.

Access DelveInsight’s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies

Hemophilia Emerging Drugs Profile

SerpinPC: Centessa Pharmaceuticals

SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data.

Fitusiran: Alnylam Pharmaceuticals

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia.

ASC 618: ASC Therapeutics

ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration.

The Hemophilia Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment.
Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market.

Get a detailed analysis of the latest innovations in the Hemophilia Pipeline. Explore DelveInsight’s expert-driven report today! @ Hemophilia Unmet Needs

Hemophilia Companies

Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.

Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives

Scope of the Hemophilia Pipeline Report

Coverage- Global
Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others.
Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others.
Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight’s exclusive Pipeline Report—access it now! @ Hemophilia Emerging Drugs and Major Companies

Table of Contents

Introduction
Executive Summary
Hemophilia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hemophilia– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Fitusiran: Alnylam Pharmaceuticals
Mid Stage Products (Phase II)
SerpinPC: Centessa Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company Name
Preclinical and Discovery Stage Products
Drug name: Company Name
Inactive Products
Hemophilia Key Companies
Hemophilia Key Products
Hemophilia- Unmet Needs
Hemophilia- Market Drivers and Barriers
Hemophilia- Future Perspectives and Conclusion
Hemophilia Analyst Views
Hemophilia Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia Clinical Trial Pipeline Shows Potential with Active Contributions from 80+ Key Companies | DelveInsight

Hepatic Tumor Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026”report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the Hepatic Tumor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatic Tumor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hepatic Tumor Pipeline @ https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight

Key Takeaways from the Hepatic Tumor Pipeline Report

On February 20, 2026- Crinetics Pharmaceuticals Inc. announced a phase 3 study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome. The study includes a screening period of up to 11 weeks, a double-blinded randomized control period of 16 weeks, an open label extension period of 104 weeks, and a follow-up period of 4 weeks.
On February 09, 2026- Stanford University conducted a Phase II Trial of REal Time MRI GUided Adaptive Stereotactic Ablative Radiotherapy for Liver Cancers Using a Single Session, Simulation Free Workflow
DelveInsight’s Hepatic Tumor pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Hepatic Tumor treatment.
The leading Hepatic Tumor Companies such as Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.
Promising Hepatic Tumor Pipeline Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, NIK-333(peretinoin), Sorafenib, SonoVue®, Talaporfin sodium, NV1020, Pemetrexed, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hepatic Tumor Treatment Drugs

Hepatic Tumor Emerging Drugs Profile

Namodenoson: Can Fite Biopharma

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is an oral drug currently being developed for the treatment of oncology diseases including advanced liver cancer (hepatocellular carcinoma), pancreatic cancer and metabolic associated steatohepatitis (MASH). Currently it is in Phase III stage of clinical trial evaluation to treat Hepatocellular Carcinoma.

MTL CEBPA: MiNA Therapeutics

MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-a protein to normal levels using the RNA Activation mechanism. The drug candidate uses the RNA interference mechanism of action. Currently being evaluated in the Phase II studies for the treatment of Hepatic Tumor.

Amivantamab: Janssen Research & Development, LLC

Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. The drug is based on antibody-dependent cell cytotoxicity mechanism of action. The drug is in Phase II stage of clinical trials for the treatment of Hepatic Tumor.

Fostroxacitabine bralpamide: Medivir AB

Fostroxacitabine bralpamide is a small molecule a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. being developed by Medivir AB. It works as Nucleotide DNA polymerase inhibitor. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I/II for the treatment of Hepatic Tumor.

ETN101: Etnova Therapeutics Corp.

ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It is being developed with the aim of preoccupying the market for both first-line and follow-up treatments of hepatocellular carcinoma with its high rate of complete remission and safety. It inhibits protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and its downstream signaling pathways: PI3K/AKT and RAS-MAPK, working as multiple tyrosine kinase inhibitors (mTKI). The drug is in Phase I stage of clinical trials for the treatment of Hepatic Tumor.

The Hepatic Tumor Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hepatic Tumor with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatic Tumor Treatment.
Hepatic Tumor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hepatic Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatic Tumor market

Explore groundbreaking therapies and clinical trials in the Hepatic Tumor Pipeline @ New Hepatic Tumor Drugs

Hepatic Tumor Companies

Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.

Hepatic Tumor Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
intravenous
Subcutaneous
Topical.

Hepatic Tumor Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hepatic Tumor Market Drivers and Barriers

Scope of the Hepatic Tumor Pipeline Report

Coverage- Global
Hepatic Tumor Companies- Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., and Eureka Therapeutics Inc and others.
Hepatic Tumor Pipeline Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, NIK-333(peretinoin), Sorafenib, SonoVue®, Talaporfin sodium, NV1020, Pemetrexed, and others.
Hepatic Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatic Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Hepatic Tumor Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Hepatic Tumor: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Comparative Analysis
Namodenoson: Can Fite Biopharma
Mid Stage Products (Phase II)
MTL CEBPA : MiNA Therapeutics
Early Stage Products (Phase I)
Comparative Analysis
ETN101: Etnova Therapeutics Corp.
Inactive Products
Hepatic Tumor Key Companies
Hepatic Tumor Key Products
Hepatic Tumor – Unmet Needs
Hepatic Tumor – Market Drivers and Barriers
Hepatic Tumor – Future Perspectives and Conclusion
Hepatic Tumor Analyst Views
Hepatic Tumor Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatic Tumor Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight

Top Real Estate Listing Agent in Cape Coral, FL, Highlights Strategic Pricing as Key Factor in Today’s Southwest Florida Market

Cape Coral, FL – As Southwest Florida’s real estate market becomes more measured, success increasingly depends on strategic approach rather than speed alone. Proper pricing and professional presentation have emerged as critical factors separating listings that sell smoothly from those experiencing extended market time.

Jenn Spears, Cape Coral, FL Realtor, reports that overpricing continues to result in longer market exposure, while competitively priced properties generate stronger buyer interest from the start. “Today’s buyers are analytical,” explains Ashworth. “They compare multiple properties carefully before making decisions, which means pricing accuracy matters more than ever.”

Jenn Spears, Realtor agent in Cape Coral, FL, emphasizes that presentation quality significantly influences perceived value. “Professional marketing, staging, and attention to property condition help homes stand out in a market where buyers have options,” says Spears. “Sellers who adapt to current expectations consistently see stronger outcomes.” Data shows that properly priced listings receive offers an average of three weeks faster than overpriced comparables in the same neighborhoods.

Re/Max Realty Team: Bob Ashworth PA & Jenn Spears Real Estate Agents in Cape Coral FL specializes in developing customized marketing strategies that showcase properties effectively. As an experienced real estate listing agent in Cape Coral, FL, Jenn Spears and the team provides honest market assessments that help sellers establish realistic pricing from day one.

Their detail-oriented approach includes comprehensive market analysis, professional photography, and strategic positioning that attracts qualified buyers. As a respected Cape Coral, FL Realtor agent, Spears brings certified negotiation expertise to every transaction, ensuring clients achieve optimal results regardless of market conditions.

“Preparation and transparency are what drive success in today’s environment,” notes Spears. “Sellers who work with knowledgeable professionals and price strategically position themselves for smooth transactions.”

Considering selling your Southwest Florida property? Visit http://bobashworthrealty.com/ to connect with real estate professionals who combine market expertise with proven marketing strategies. Re/Max Realty Team delivers results through straightforward communication and commitment to client satisfaction from first meeting through closing.

Media Contact
Company Name: Re/Max Realty Team: Bob Ashworth PA & Jenn Spears Real Estate Agent in Cape Coral FL
Contact Person: Bob Ashworth
Email: Send Email
Phone: +1 239-898-2716
Address:2326 Del Prado Blvd S
City: Cape Coral
State: Florida
Country: United States
Website: bobashworthrealty.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Listing Agent in Cape Coral, FL, Highlights Strategic Pricing as Key Factor in Today’s Southwest Florida Market